TNGX - Tango Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Cambridge,
United States
Type: Equity
TNGX price evolution
TNGX
| (in millions $) | 31 Jan 2024 | 30 Oct 2023 | 30 Jul 2023 | 1 May 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $346.54 | $370.89 | $320.54 | $343 |
| Long term investments | ||||
| Property, plant & equipment | $53.42 | $54.68 | $56.21 | $57.33 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $402.57 | $428.19 | $379.33 | $403.77 |
| Current liabilities | ||||
| Accounts payable | $2.79 | $2.84 | $4.79 | $6.3 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $45.94 | $43.42 | $53.63 | $53.67 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $149.46 | $151.59 | $166.38 | $176.51 |
| Shareholders' equity | ||||
| Retained earnings | -$371.26 | -$340.49 | -$318.23 | -$297.52 |
| Other shareholder equity | $0.19 | -$0.68 | -$1.52 | -$2.2 |
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $1.31 | |||
| Short term investments | ||||
| Net receivables | $2 | $2 | ||
| Inventory | ||||
| Total current assets | $346.54 | $375.27 | $492.34 | $1.5 |
| Long term investments | ||||
| Property, plant & equipment | $53.42 | $57.77 | $6.09 | |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $402.57 | $436.47 | $500.15 | $168.31 |
| Current liabilities | ||||
| Accounts payable | $2.79 | $4.45 | $3.23 | |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $45.94 | $55.55 | $40.69 | $0.11 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $149.46 | $186.99 | $155.41 | $5.95 |
| Shareholders' equity | ||||
| Retained earnings | -$371.26 | -$269.51 | -$161.34 | -$0.12 |
| Other shareholder equity | $0.19 | -$3.71 | -$0.77 | |
| Total shareholder equity | ||||
| (in millions $) | 29 Oct 2022 | 29 Jul 2022 | 30 Apr 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $6.92 | $5.77 | $5.76 | $5.72 |
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $36.84 | $30.97 | $31.14 | $27.7 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $0 | $0.18 | ||
| Interest expense | $0.35 | $0.3 | $0.22 | $0.2 |
| Net income | ||||
| Net income | -$29.05 | -$24.86 | -$25.21 | -$22.05 |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2022 | 31 Jan 2021 | 31 Jan 2020 | |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $37.04 | |||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $95.23 | $0.18 | ||
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $0.29 | $0.01 | ||
| Interest expense | $0.49 | $0.07 | ||
| Net income | ||||
| Net income | -$58.23 | -$0.12 | ||
| Income (for common shares) | ||||
| (in millions $) | 29 Oct 2022 | 29 Jul 2022 | 30 Apr 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | $39 | $23.78 | -$11.72 | -$183.43 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $1.09 | $0.97 | $0.26 | $357.32 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$40.72 | -$36.45 | -$41.13 | $114.36 |
| (in millions $) | 31 Jan 2022 | 31 Jan 2021 | ||
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$183.43 | -$166.75 | ||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $357.32 | $168.39 | ||
| Effect of exchange rate | ||||
| Change in cash and equivalents | $114.36 | $1.31 | ||
News
Fundamentals
| Market cap | $753.23M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 102.20M |
| Revenue | $24.16M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$101.16M |
| Revenue Q/Q | 1.96% |
| Revenue Y/Y | N/A |
| P/E ratio | -7.45 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 31.17 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$0.99 |
|---|---|
| ROA | -25.07% |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 7.54 |
| Quick ratio | N/A |